NICE· @NICEComms · X·· 1 小时前精选AI 评分62
AI 导读
NICE 发布最终指南，推荐达雷妥尤单抗联合硼替佐米、来那度胺和地塞米松，用于适合接受干细胞移植的未经治疗多发性骨髓瘤患者。NICE 称约 1,750 名多发性骨髓瘤患者可能从这一新治疗选择中获益。
推荐理由
NICE 最终指南将达雷妥尤单抗联合方案纳入未经治疗多发性骨髓瘤，读者可了解英国报销准入的适用人群范围。
正文
Around 1,750 people with multiple myeloma could benefit from a new treatment option.
NICE final guidance recommends daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma in people eligible for a stem cell transplant https://www.nice.org.uk/guidance/ta1195?utm_medium=organic&utm_source=x&utm_campaign=daratumumab_300926&utm_content=finalvideo
来源：NICE · x.com